Enzyme-Linked Immunosorbent Assay
Human Anti-Ranibizumab Antibody antigen capture ELISA for pharmacokinetic assay developmentA microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of ranibizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29928 at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
Enzyme-Linked Immunosorbent Assay
Human Anti-Ranibizumab Antibody antigen capture ELISA for pharmacokinetic assay developmentA microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of bevacizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29865 at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
Enzyme-Linked Immunosorbent Assay
Human Anti-Ranibizumab Antibody antigen capture ELISA for pharmacokinetic assay developmentA microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of ranibizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29928 at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
Enzyme-Linked Immunosorbent Assay
Human Anti-Ranibizumab Antibody antigen capture ELISA for pharmacokinetic assay developmentA microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of bevacizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29865 at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
Enzyme-Linked Immunosorbent Assay
Human Anti-Ranibizumab Antibody antigen capture ELISA for pharmacokinetic assay developmentA microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of ranibizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29928 at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
Enzyme-Linked Immunosorbent Assay
Human Anti-Ranibizumab Antibody antigen capture ELISA for pharmacokinetic assay developmentA microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of bevacizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29865 at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
Enzyme-Linked Immunosorbent Assay
Human Anti-Ranibizumab Antibody antigen capture ELISA for pharmacokinetic assay developmentA microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of ranibizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29928 at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.
Enzyme-Linked Immunosorbent Assay
Human Anti-Ranibizumab Antibody antigen capture ELISA for pharmacokinetic assay developmentA microtiter plate was coated overnight with recombinant human VEGF-A at a concentration of 5 µg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of bevacizumab. Detection was performed using Human Anti-Ranibizumab Antibody, clone AbD29865 at a concentration of 2 µg/ml and a rat anti-DYKDDDDK-tag antibody in HISPEC Assay Diluent followed by QuantaBlu Fluorogenic Peroxidase Substrate. Data are shown as the mean of three measurements.